Skip to main content
. Author manuscript; available in PMC: 2019 Jan 22.
Published in final edited form as: Neuropharmacology. 2017 Nov 8;129:36–46. doi: 10.1016/j.neuropharm.2017.11.012

Fig. 3.

Fig. 3

Effects of methamphetamine alone or in combination with RO5263397 on 5-CSRTT performance during chronic methamphetamine treatment. ‘Pre-chronic’ (column 1) represent data collected prior to initiation of chronic methamphetamine, no RO5263397 was administered in either group. ‘Cycle 1’ (column 2) represent data collected on days 7 – 10 of daily methamphetamine treatment. ‘Cycle 2,’ ‘cycle 3,’ and ‘cycle 4’ (columns 3 – 5) represent data collected on days 17 – 20, 27 – 30, and 37 – 40 of chronic methamphetamine treatment, respectively. In cycles 1 – 4, 5.6 mg/kg RO5263397 was administered to the group labeled ‘5.6 RO’ prior to each test. See Figure 1 for ordinates. Abscissas are the dose of methamphetamine in mg/kg. *P < 0.05, ***P < 0.001 main effect of RO5263397 treatment according to two-way mixed-model ANOVA.